

Index

The page numbers in “**bold**” are tables and those in “*italics*” are figures.

5-HT ₃ serotonergic, 179	acute stress disorder (ASD), 168	consumption patterns, 179
absolute risk	anxious mood and, 134	dependence, 219
calculating, 12	diagnosis of, 170	depressive symptoms and, 83
first-degree relative and, 12	treatment of, 174	detoxification from alcohol
of schizophrenia, 14	vs. depression, 430–431	use, 206–207
abstinence syndromes,	with depressed mood, 84	disulfiram for treatment of,
190–191	adolescents	210, 213
babies and treatment for	evidenced-based prevention	early intervention and
opioid, 192	programs and, 228	prevention, 179
physical examination and, 191	psychiatric disorders and, 2	family history of, 185–187
Academy of Cognitive Therapy,	psychiatry, 318	FDA approved medications
396	psychotic symptoms and, 30	for, 210
acamprosate, 209–210, 372	substance use disorders and,	known history of, 198
acceptance and commitment	227	naltrexone for treatment of,
therapy (ACT), 156	substance use disorders	208–209
acetylation, histone, 18	screening tools, 227	psychoactive properties of,
acetylcholinesterase inhibitors	adoption studies, 186	179
(ACHEIs), 277, 374–375	adrenocorticotropin hormone	specialized mental health
NMDA combination therapy,	(ACTH), 27	counseling, 435
375	advanced sleep phase disorder	statistics and, 184
acute and transient psychotic	(ASPD), 337, <i>See also</i>	suicides and, 184
disorder (ATPD), 107	sleep disorders	treatment of, 203, 208–211,
acute grief, 443, 444	Affordable Care Act (ACA)	218, 229
acute intoxication, 190, 191, 419	2010, 475	withdrawal seizures and,
acute opioid intoxication, 196	and parity protections, 477	179
acute stress disorder (ASD),	agonist therapy	Alcohol Use Disorders
153, 166, 167, 168, 169	buprenorphine for treatment	Identification Test
case, 176	of opioid use disorders, 212	(AUDIT), 199
etiological insights into, 174	methadone for treatment	Alcoholics Anonymous (AA),
future directions for	of opioid use disorders,	204, 210, 216, 395
treatment of, 175	211–212	aldehyde dehydrogenase, 187
sample interview questions,	agoraphobia, 129, 132, 133	algorithm-driven care, 434
175	case example, 142–143	allostasis, 191
treatment of, 171–172	phobic neurosis diagnosis,	alpha-2 adrenergic agonists,
acute syndromes, substance	129	377
use disorders and,	alcohol dehydrogenase, 187	Alzheimer’s Association, 266
195–197	alcohol use disorders, 52, 179,	Alzheimer’s disease (AD), 124,
addiction	191, 200	267, 373
behavioral change and, 403	acamprosate for treatment	Anti-Amyloid Treatment, 283
medication for, 371–373	of, 209–210	cause of dementia, 265
risk for, 345	Alcohol Use Disorders	interventions for, 283
adjustment disorders, 166–167,	Identification Test	major or mild NCD, 263
168, 169	(AUDIT), 199	medications for, 279
		Memantine and, 279

- Alzheimer's disease (AD) (*cont.*)
 neurocognitive disorders due to, 268–269
 stages of, 266
- American Academy of Child and Adolescent Psychiatry (AACAP), 319
- American Academy of Neurology, 275
- American Board of Psychiatry & Neurology (ABPN), 2
- American Psychiatric Association (APA), 43, 303, 459, 460
- American Psychological Association (APA), 453, 459, 460, 466
- anabolic-androgenic steroids, 183
- aneuploidy, 13
- anhedonia. *See* depressive disorders
- anorexia nervosa (AN), 289,
 See also eating disorders
 crossover to bulimia nervosa and, 294
 mortality and, 293–294, 300
 recovery and relapse, 292–293
 treatment options for, 304–305
 weight loss and, 297
- antagonist therapy
 naltrexone for treatment of opioid use disorders, 213
- anticonvulsants
 mood-altering, 365, 365–366
 mood-stabilizing, 363
- antidepressant medication. *See* antidepressants
- antidepressants, 10, 76, 88, 306, 335, 342–343, 378, 390
 adverse effects, 346–347
 adverse effects of, 347
 antidepressant-related emergencies and, 348–351
 choosing, 351
 classification of, 343–346
 discovery of, 19
 rapid-acting, 352–353
 self-assessment questions, 387–388
 treatment duration, 351
 treatment of bulimia nervosa with, 305
- tricyclic antidepressants, 137, 279, 281, 333, 342, 344, 345, 361, 378
 use for anxiety disorders, 136–137
- anti-NMDA-receptor encephalitis, 25
- antipsychotic drugs, 10, 353–358
 adverse effects of, 360–362
 atypical antipsychotics, 278
 long-term treatment, 359
 short-term treatment, 356–359
 use for anxiety disorders, 137
- antipsychotic-antimanic drugs, 366
- antisocial personality disorders (ASPD), 64, 246–247
 cluster B disorders, 245–246
 malingering and, 439
 treatment, 246–247
 violent behavior and, 64
- anxiety disorders
 and children, 321
 Anxiety Disorders Interview Schedule (ADIS), 135
 case examples, 141–142
 changes to classification of, 140
 classification of, 128–129
 clinical features and course of, 130–131
 diagnosis, 133–134
 epidemiology, 129
 etiological formulations, 139
 evaluation, 134–135
 FDA approved SSRIs and SNRIs, 137
 genetic risks of, 12–13
 medical comorbidities and, 129–130
 sample interview questions, 140–141
 self-assessment questions, 144–145
 social and economic burden of, 130
 suicidal ideation and behaviors, 130
 treatment, 135–138
- anxiolytics and hypnotics, 370–371
- anxious distress, 74
- Applebaum, P. S., 67, 431
- appreciation, 68, 431
- arousal/regulatory systems, 6
- Asian population, alcohol consumption among, 187
- Asperger's syndrome, 243
- assertive community treatment (ACT), 401
- associated management strategies, 424–426
- Association of American Medical Colleges (AAMC), 2
- Atomoxetine* (Strattera), 377
- attention deficit hyperactivity disorder (ADHD), 345
 heritability and, 4
 medicines for, 375
- attenuated psychosis syndrome, 107
- atypical anorexia nervosa, 291
- AUDIT-Consumption (AUDIT-C), 200
- autism spectrum disorders (ASD), 153
- ADHD genetic overlap and, 18
- communication and, 322
- food-related anxiety and, 296
- heritability and, 4
- heritability and, 13
- high functioning variants of, 243
- paternal age and, 110
- risks for developing, 14
- avoidant personality disorders (AVPD), 242, 243, 255–256
 treatment, 255–256
- avoidant/restrictive food intake disorder (ARFID), 290, 294, 295
- Babinsky, Joseph, 9
- bath salts, 181, 193, 196
- BDD-Symptom Scale, 155
- Beach, Frank, 459
- Beck, Aaron, 393
- behavioral and physical health systems, siloed, 478–479
- behavioral couples therapy (BCT), 218
- behavioral health
 behavioral health provider (BHP), 3

- billing for services of health care managers, 480
 inadequate insurance coverage for, 476–477
 integrated care, 220–221
 integrated with primary care and, 3–4, 432–433
 integration of with physical health care, 482
 treatment of disorders and, 473
 behavioral learning theory interventions, 216–217
 behavioral therapies, 219
 pharmacotherapy use with, 219–220
 substance use disorders and, 214–215
 Benson, Herbert, 409
 benzodiazepines, 135–136
 bereavement, 85–86, 443–444
 beta-blockers, 135
 used for anxiety disorders, 137
 binge-eating disorder (BED), 290, 295, *See also* eating disorders
 episode of, 291
 recovery and relapse, 293
 treatment options for, 306
 biofeedback, 408, 410
 bipolar disorders
 anticonvulsants in treatment of, 365–366
 children and adolescents and, 319–320
 classification of, 89–90
 clinical course, 90
 duration of treatment for, 98
 effect of on other medical illness, 91
 electroconvulsive therapy (ECT) treatment for, 381
 epidemiology of, 320
 evaluation of patient, 96–97
 full remissions, 94
 genetics and, 12
 heritability and, 4
 hypomanic episode phase, 93–94
 incidence of, 12
 long-term prophylactic treatment for, 367–368
 major depressive disorder (MDD) and, 91, 95
 manic episode, 91–93
 medication-induced, 90, 95
 mood-stabilizing drugs for, 362–365
 morbidity and mortality, 90
 other mental conditions and, 95
 prevalence of, 90, 320
 psychotic symptoms and, 92
 recurrent episodes of, 94
 risk assessment and, 97
 second-generation antipsychotics in, 364
 substance-induced, 95
 suicide and, 94
 treatment options for, 97–98
 blood alcohol content (BAC), 195
 Blood Oxygen Level Dependent (BOLD) signal, 30
 body dysmorphic disorder (BDD), 146, 147
 case example, 159
 borderline personality disorder (BPD), 76, 234, 245, 247–251, 396
 cognitive-behavioral treatment and, 396
 skill deficit remediation and, 394
 treatment of, 249–251
 borderline schizophrenia, 240
 boundaries, between clinicians and patients, 41–42
 brain function, 26, 28, 125
 biological basis of, 20
 circuit-based understanding of, 9
 connection between immune molecules and, 24, 26
 emotional phenomena, 9
 mental homeostasis and, 390
 psychotherapeutic treatments and, 389
 brain imaging techniques, 10
 Brain on Fire, 25
 brain pathology
 history and clinical syndromes, 9–10
 brain signaling molecules, 19–22
 brexanolone, 353
 brief psychotic disorder, 106–107
 psychotic symptoms, 106
 brief reactive psychosis, 107
 Broca, Paul, 9
 building blocks
 for mental health, treatment modalities and, 394
 bulimia nervosa (BN), 289, 291, *See also* eating disorders
 crossover to anorexia nervosa, 294
 mortality and, 300
 recovery and relapse, 293
 treatment options for, 305–306
 buprenorphine, 204, 212
 for opioid dependence, 372
 opioid use disorders treatment, 212
 treatment of opioid withdrawal, 208
 bupropion, 348
 Cade, John, 364
 cancer
 depression and, 72
 heritability of ovarian, 13
 cannabinoids, 181, 192
 cannabis use disorders, 208, 214
 adolescents and young adults, 188
 cannabis intoxication, 192
 psychotic disorder and, 228
 schizophrenia and, 110
 treatment for, 181
 capacity
 assessment, 66–68
 decision-making, 431
 evaluations, 432
 self-assessment questions, 69
 Carlsson, Arvid, 19
 catatonia, 94
 electroconvulsive therapy (ECT) treatment for, 381
 major depression and, 76
 Center for Transgender Excellence, 464
 Centers for Disease Control and Prevention (CDC), 180, 318, 342, 451
 central sigma receptors, 182
 central sleep apnea syndromes, 338, 339, *See also* sleep disorders

- cerebrovascular health and cognitive functioning, 282
- characterologic dysphoria, 84
- Charcot, Jean-Martin, 9
- chief complaint, 44
- child and adolescent psychiatry, 318, 323
 - shortage of child psychiatrists, 3
- child- and family-focused cognitive behavior therapy (CFF-CBT), 320
- child/children
 - anxiety disorders and, 321
 - depression and, 318
 - depressive disorders in, 320–321
 - disinhibited social engagement disorder and, 323–324
 - post-traumatic stress disorder (PTSD) and, 324
 - psychiatric disorders and, 2
 - psychotic symptoms in, 324–326
 - selective mutism and, 322
 - separation anxiety disorder and, 322
 - specific phobia and, 322
 - substance use disorders and, 227
 - treatment for depression in children, 320
- Chisholm, Brock, 1
- chlorpromazine, 19
- chronic disease management strategies, 434
- cigarette smoking, decline of, 180
- circadian rhythm disorders, 337–338
- circuits
 - and brain signaling molecules, 19–22
 - converging, 28–32
- classification systems, 5
- Client-Centered Therapy, 405
- mind-body therapies,
- Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar), 198
- clinical interview, patients with MDD and, 86–87
- clinical neurosciences, 7, 9, 33, 34, 35
 - self-assessment questions, 36
- Clinical Opiate Withdrawal Scale (COWS), 198
- clinical psychiatry, 6, 9, 26, 38
 - and symptom-based diagnoses, 6
- clinician-rated instruments, 153
- club drugs, 193
- clubhouses, 402
- cluster disorders
 - cluster A disorders, 240–241
 - cluster B disorders, 245–246
 - cluster C disorders, 254–255
- cocaine, 23, 95, 181, 184, 188, 193, 196, 214, 350, 376, 468
 - administration in mice, 18
 - dependence, 219
 - intravenous, 187
 - withdrawal phases of, 83
- cognitive and attentional disorders
 - medications for, 373–375
- cognitive behavior therapy (CBT), 138, 171, 175, 217–218, 312, 321, 324, 351, 393–396, 397
 - obsessive-compulsive disorders (OCD) and, 155
 - therapy for depression in children, 319
 - treatment for insomnia, 330
 - treatment option for eating disorders, 301–302
- cognitive impairment
 - differential diagnosis and, 272–273
 - evaluation, 273
- cognitive processing therapy (CPT), 172
- cognitive reserve model, 277, 282
- cognitive systems, 6
- cognitive therapy (CT),
 - treatment for OCD, 155
- collateral history, 423, 430
- collateral history', 427
- common variants, searching for, 14–16
- compassion fatigue, 442
- compassion, patient interview process and, 40–41
- complex disorders, polygenic, 4
- confusional arousals, 334
- consultation-liaison psychiatry/psychiatrists, 422, 431, 432
- contingency management (CM), 216–217
- copy number variants (CNVs), 4, 15
- corticotropin-releasing hormone (CRH), 27
- Cotard's syndrome, 75
- COVID-19, 7
 - neuropsychiatric manifestations of, 24
- CRAFT screen, 201–203
- cue exposure, 216
- cyclothymic disorder, 362
 - diagnostic criteria for children, 320
- cytochrome p450 system, 15
- deacetylation, 18
- deep brain stimulation (DBS), 384
- deep TMS device, 383
- Delay, Jean, 19
- delayed sleep phase disorder (DSPD), 337
- deletion syndrome, 14
- delirium, 263–279, 280
 - clinical features and onset, 264–265
 - evaluation of, 274
 - precipitating factors and, 280
 - predisposing factors for, 280
 - treatment of, 275–276
- delusional disorder, 105–106
 - diagnostic criteria, 105
 - specify types of, 105–106
- delusions
 - psychotic depression and, 75
- dementia
 - age and, 265
 - associated neuropsychiatric syndromes treatment, 278
 - behavioral and psychological symptoms of, 277–280

- cases, 285
 cognitive symptoms of, 277
 dementia electroconvulsive therapy, 280
 electroconvulsive therapy (ECT) for, 381
 factors for delirium, 281
 future research and, 283–284
 neurodegenerative, 270, 373
 new treatments for, 375
 prevalence rates for, 283
 progressive, 266
 progressive neurodegenerative, 263
 sample interview questions, 284
 self-assessment questions, 286–287
 treatments for neuropsychiatric symptoms, 278–280
 dementia praecox, 102, 115, 125
 demoralization, 85, 132
 denial
 of a problem, 205
 response to illness, 195, 429–430
 Deniker, Pierre, 19
 dependent personality disorder (DPD), 255–256
 dependent personality disorder (DPD), 256–257
 depressive disorders, 79, 81, 86, 94, 346
 adjustment disorders and, 84
 alcohol use disorders and, 83
 anxiety and, 74
 bereavement and, 85–86
 bipolar disorders and, 94
 children and, 318
 classification of, 70
 depressed mood or anhedonia, 73, 79
 depression,
 disruptive mood dysregulation disorder, 320–321
 disruptive mood regulation disorder and, 82
 electroconvulsive therapy (ECT) treatment for, 380
 epidemiology of and children, 318
 episode specifiers, 94
 following medical illness, 72
 medication-induced, 83
 mild depression and, 79
 mixed mood features and, 75
 morbidity and mortality and, 72
 neurovegetative symptoms of, 86
 persistent, 79–81
 rapid-acting antidepressants and, 353
 related to another medical condition, 82–83
 remission from, 79
 seasonal variation pattern of, 77
 self-assessment questions for children and adolescents, 327–328
 severe depression and, 64, 79, 89
 severe depression and electroconvulsive therapy, 98, 280
 short-term treatment for, 366–367
 statistics, 80
 substance-induced, 83
 treatment of, in children, 319
 treatment options for, 87–89
 treatment-resistant depression (TRD), 352
 unipolar depression in children, 321
 detoxification
 alcohol use disorders, 206–207
 from other drugs, 208
 medically-supervised, 179
 opioids, 207–208
 program for severe alcohol use disorders, 435
 sedative-hypnotics, 206–207
 diagnosable mental disorder, 1
 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 5, 70, 128, 146, 189, 436
 (DSM-IV-TR), 166
 diagnoses, 50
 Diagnostic and Statistical Manual (DSM), 10
 psychiatric diagnoses of gender and sexual orientation and, 460
 system of categorization, 5
 dialectical behavior therapy (DBT), 156, 250, 394, 395, 396–398
 diffusion tensor imaging (DTI), 30
 discontinuation (withdrawal syndromes), 379–380
 disinhibited social engagement disorder, 323–324
 dissociative drugs, 182, 193, 196
 disulfiram, 210, 213
 dizygotic twins, 12, 308
 domestic violence, 56
 assessing the risk, 59–60
 care with mental illness diagnosis, 60–61
 clinical documentation in, 60–61
 clinical presentations of, 57
 definition of, 56–57
 interventions and, 61
 outcomes and, 61
 prevalence and impact of, 57
 referring victims to help, 60
 screening and assessment, 58–59
 Dominantly Inherited Alzheimer's Network (DIAN), 283
 dopamine D2 receptor (*DRD2*), 16
 dopamine system, 21, 22, 124
 dopamine transporter (DAT), 23
 Down's syndrome, 272
 drug allergies, 47
 Drug Assessment Screening Tool (DAST-10), 200
 drug overdose, 2
 drug reinforcement, 187
 drug use disorders, 214
 statistics and, 184
 Durable Power of Attorney for Health Care, 68

- dysphoria, 24, 52, 86, 182, 278, 290, 394
and personality disorders, 84
gender, 460–461, 464–465, 469
dysphoric mania, 92
- eating disorders
adult case example, 312–313
anorexia nervosa (AN), 31, 289, 291
bulimia nervosa (BN), 291
child cases of, 313–314
classification of, 289–291
course and outcome for, 292
diagnostic crossover and, 294
differentiating from normative behaviors, 297
differential diagnosis and, 295–296
differentiating from a medical disorder, 296–297
directions for research, 310
epidemiology and impact of, 291–292
etiological factors and, 291–292
evaluation of, 298–299
family-based treatments (FBT) for, 302–303
future research and, 309
management team for treatment of, 307
mortality and, 293–294
neurobiological risk factors for, 308
not otherwise specified (EDNOS), 291
pharmacologic management of, 304
recovery and relapse, 292–294
residential and inpatient treatment for, 303–304
sample interview questions, 311
self-assessment questions, 316–317
supplemental questions, 311–312
suspected, 299–301
treatment approaches for, 301–307
types of, 289–290
- electroconvulsive therapy (ECT), 76, 342, 380–381, 389
cognition and, 381–382
safety and adverse effects of, 381
Ellis, Albert, 393
emergency psychiatry, 415–416
empathy, 64, 76, 204, 253, 399, 404
and the patient interview process, 40–41
Employee Retirement Income Security Act (ERISA) (1974), 474
employer-sponsored health insurance (ESI), 474
endocrine system
endocrinologic disorders, 82
link to psychiatric illness, 27–28
end-of-life priorities, 441
end-stage renal disease (ESRD), 475
enzymatic attachment, 18
Epidemiologic Catchment Area (ECA) study, 184
epigenetics, 18
erotomania, 113
ethyl alcohol, 179
evidence-based psychotherapy, 88
evidenced-based prevention programs
adolescents and, 228
evidence-based screening assessments, 221
exome sequencing, 14
exposure and response prevention (ERP) component, 155
- factitious disorder, 438–440
factual understanding criteria, 67
Fagerstrom Test for Nicotine Dependence, 199
failure of humanity, a, 490
familial relative risk, 12
family and couples therapy, 218–219, *See also* family-based treatments (FBT)
family history, patients', 48
family psychoeducation, 402
- family-based treatments (FBT), 218–219, 228
eating disorders and, 302–303
Farmer, Paul, 1
feeding disorders, 290–291, 294–295
fluoxetine, 304, 305, 319, 348, 352
Ford, Clellan, 459
FRAMES model, 204–205
Freud, Sigmund, 10, 174, 393
Three Essays on the Theory of Sexuality (Freud), 456
frontotemporal neurocognitive disorder (FTNCD), 270
functional brain imaging techniques, 10
functional neural connectivity field, 7
- Galton, Francis, 456
gender and sexuality, 456–458
affirming treatment, 466–467
and non-binary/gender-expansive categories, 452–453
Diagnostic and Statistical Manual (DSM-5) diagnosis of, 460
history of psychiatric diagnoses of, 459–460
minority stress and, 458–459
psychiatric evaluation and treatment of issues with, 462–463
sexual identity development and, 456–458
gender dysphoria, 460–461, 464–465, 469
gender expression, 450, 465, 466
gender identity, 448–449
gender and, 449–451
gender identity disorder, 460
gender roles and, 450
psychiatry of sexual orientation, 456–458
sex and, 449
sexual orientation and, 448
gene, 13
DNA methylation, 18
gene expression, 18

- generalized anxiety disorder (GAD), 6, 132, 234
7-item Scale (GAD-7), 135
case examples, 141–142
genetic heritability, 186, 308
genetic mutations, age and, 110
genetic risks, 18, 24, 308
 alcohol use and, 186
 Alzheimer's disease (AD), 282
 psychiatric disorders and, 4, 12
 schizophrenia and, 25
 vascular disease risk factors and, 282
genetics, psychiatric, 4–5
Genome-Wide Association Studies (GWAS), 16–18
 use of data from, 17
genotype, 13
Global Burden of Disease study, 108
global disease burden, 184
global health, 486–487, 491
 agenda, 490
 burden of illness, 486
 delivery, 491
 global health equity, 1
 standard of clinical care, 489
global mental health care
 delivery
 self-assessment questions, 495–496
global population, growth of, 2
global treatment gaps
 and integrated health care, 3
glutamate and gamma-aminobutyric acid (GABA), 20
G-protein inwardly-rectifying potassium (GIRK) ion channels, 179
grief, 392, 443–444, 445
 acute, 444
 unbearable, 391
Griesinger, Wilhelm, 9
Grisso, T., 67
group therapy, 398–400
Guidelines for Psychological Practice with Lesbian, Gay, and Bisexual Clients, 466
hair pulling disorder (HPD), 146, 148
 case example, 160
hallucinogens, 182, 193, 197
haplotypes, 16
head imaging (CT or MRI), and patient with delirium and, 274
health care coverage
 self-assessment questions, 484–485
 United States and, 473
health care proxies, 68
health care system, 433, 482, 489
 United States, 283, 473–474, 479, 482
health insurance
 behavioral health coverage and, 476
 employer-sponsored, 474
 federal, 475
 Medicaid, 475
 Medicare, 475
 sources of coverage, 474
 universal, 473
healthy living interventions, 402
heritability
 anorexia nervosa (AN) and, 308
 antisocial personality disorders (ASPD), 246
 avoidant personality disorder (AVPD) and, 255
 borderline personality disorder (BPD) and, 248
 dependent personality disorder (DPD) and, 256
 for a disorder, 13
 genetic, 186
 histrionic personality disorder and, 251
 mental illness and, 12
 missing, 15
 narcissistic personality disorder (NPD) and, 253
 obsessive-compulsive personality disorder (OCPD) and, 257
 paranoid personality disorder (PPD) and, 241, 243
 schizoid personality disorder (SzPD) and, 243
 schizophrenia and, 16
 schizotypal personality disorder and, 244
Hispanics
 prevalence and treatment outcomes of mental disorders, 2
histocompatibility complex (MHC) locus, 17
histone acetylation, 18
histrionic personality disorder (HPD), 251
 treatment of, 252–253
HIV. *See* human immunodeficiency virus (HIV)
hoarding disorder (HD), 146, 147–148
 case example, 160
homosexuality, 459, 460
 codified as a disease, 459
hormones, 19, 28
 and mental illnesses, 26–28
 masculinizing therapy, 468
Human Connectome Project (HCP), 30
human genome, 4, 13, 16
human immunodeficiency virus (HIV)
 depression and, 72
 global health programs and, 486
 group therapy for people diagnosed with, 398
 injecting drug use and, 180, 185
 low testosterone and depressive symptoms in men with, 83
 neurocognitive disorders and, 263
 neurocognitive disorders resulting from, 271
 primary health care and, 491
 secondary mania and, 95
 stimulant use and risky behaviors and, 182
 transgender people's increased risk for, 451
human rights, and institutional care, 489
human sexuality and gender, 467
Huntington's disease, 271

- hydroponically-engineered hemp plants, 181
- hypersomnias, 335–337
- hyperthymic temperament, 96
- hypnotics and anxiolytics, 370–371
- hypothalamic-pituitary-gonadal (HPG) axis, 28
- illness
 - medical, 428
- imaging studies, 421–422
- immune cell dysfunction
 - psychiatric symptoms and, 25
- immune system, 24–26
- IMPACT Model (Improving Mood Promoting Access to Collaborative Treatment), 479–480, 481
- informed consent, 66
- inhalants, 183
- injection drug use, 180, 185
- Insel, Thomas, 10
- insomnia, 329–333
 - cognitive, 330
 - differential diagnosis of, 331
 - induced, 182
 - initial, 86
 - middle, 87
 - suicide risk and, 53
 - symptomatic treatment of, 174
 - terminal, 87
- institutional care, and human rights, 489
- integrated behavioral health care, 220–221
- integrated mental health care, 3
- integrative health care programs, 436
- Interagency Standing Committee Guidelines (IASC), 491
- International Classifications of Disease (ICD-10) system, 104
- International Genomics Consortium (PGC), 4
- International Statistical Classification of Diseases and Related Health Problems-10, 5
- interpersonal psychotherapy (IPT), for treating depression in children, 319
- intersex traits, 452
- intoxication syndromes, 183
- intrauterine opioid exposure, 192
- Kinsey, Alfred, 459
- Kleinman, Arthur, 490
- Kraepelin, Emil, 102
- laboratory studies
 - psychiatric symptoms and, 420–421
- Lewy bodies, 263, 265, 335
 - neurocognitive disorder due to, 269–270
- LGBTQ people, 457, 458–459, 460, 463
 - affirming treatment and, 466–467
 - health disparities and, 458
 - psychiatric evaluation of, 463–464
- Liebenluft, Ellen, 320
- Liebowitz Social Anxiety Scale (LSAS), 135
- life expectancy
 - of people with mental illnesses, 2
 - United States, 476
- lifestyle
 - behavioral therapies and modification of, 215
 - changes for improved health, 435
 - cognitive behavior therapy (CBT), 396
 - eating disorders and healthy, 298
 - of people with schizophrenia, 402
 - patients', 47
 - sedentary, 308
 - somatic symptom disorders and a healthy, 437
 - substance use disorders and, 194
- ligands, 180
- Lindqvist, Maria, 19
- linkage disequilibrium*, 16
- Lisdexamfetamine dimesylate (LDX), 306
- lithium salts, 364–365
- locus*, 13
- long term depression (LTD), 20
- long-term antipsychotic treatment, 359–360
- lower socioeconomic groups and schizophrenia, 110
- maintenance therapies, 371–373
- major depression. *See* major depressive disorders
- major depressive disorder (MDD), 6, 73–74, 234
 - atypical features of, 76, 91
 - bipolar disorder and, 95
 - catatonia and, 76
 - clinical course and, 71–72
 - clinical findings and, 431
 - clinical interview of patients, 86–87
 - DSM criteria for children, 318
 - DSM-5 diagnostic criteria, 73, 73–74
 - laboratory evaluation of patient with MDD, 87
 - melancholic features of, 75–76
 - morbidity and mortality and, 72
 - norepinephrine depletion, 19
 - onset of, 71–72
 - peripartum onset and, 77
 - persistent depressive disorder and, 79–81
 - physical exam of patient, 87
 - prevalence of, 71
 - risk assessment of, 87
 - self-assessment questions, 100–101
 - serotonin depletion and, 19
 - suicide and, 77–79
 - treatment duration of, 351
 - unipolar major depressive disorder, 89
 - with psychotic features, 75
- major depressive disorders (MDD)
 - psychotic symptoms and, 75
- major psychiatric disorders
 - discovery of pharmacological treatments for, 10

- malingering, 438–440
Manhattan plot, 16
 mania and psychotic disorders
 pharmacological treatment, 353
 MAPS TO diagnosis, 45
 marijuana. *See* cannabinoids
 masculinizing hormone
 therapy, 468
 Massachusetts General Hospital
 Hairpulling Scale, 155
 mediated neurotransmission, 179
 Medicaid, 266, 475–476
 medical and behavioral health
 care, integration of, 479–480
 medical detoxification, 206
 medical history, 47
 medical illnesses/problems, 7, 24, 82, 95, 251, 277, 417, 420, 428, 439
 anxiety disorders and, 130
 behavioral factors and, 479
 bipolar disorders impact on, 91
 emotional responses to, 428–430, 429
 impact of mental illness on, 72
 mental illness and, 2
 psychiatric, 1
 psychotic disorders and, 105
 untreated psychiatric illness and, 123
 Medicare, 266, 475, 478, 480, 481
 Medicare Advantage, 475
 medications
 adhering to treatment, 378
 confirming using, 427
 current, 47
 for attention deficit hyperactivity disorder (ADHD), 375
 mood-altering, 369
 meiosis, 16
 memantine, 277, 278, 375
 menopause, 71
 mental disorders
 classification of, 5–6
 diagnosable, 1
 future diagnostic system and, 5–6
 treating when comorbid with an eating disorder, 306–307
 worldwide prevalence of, in children and adolescents, 2
 mental health
 clinicians, 4, 62, 433, 465
 co-co-location of providers, 479
 co-location of providers, 435
 global challenges in care delivery, 492
 increase need for treatment, 2
 integrated care, 3
 integration of treatment, 3
 models of care, 433
 neglected healthcare, 7
 providers, 482
 providers, 434
 shortage of clinicians, 3
 treatment gap, 488
 treatment settings, 247
 treatments, 487
 workforce shortage and, 2–3
 mental health care delivery
 global, 489–491
 nonspecialist, 489–491
 task sharing and, 489–491
 Mental Health Gap program, 490
 Mental Health Parity Act, 477
 Mental Health Parity and Addiction Equity Act (MHPAEA), 477
 mental health services
 decentralization of, 491–492
 mental homeostasis, 390
 mental illnesses
 assessing risks posed to others, 62
 cultural factors and, 72
 global impact of, 487
 heritability, 14
 human suffering and, 1
 life expectancy and, 6
 patients and risk factors for violence, 62–63
 relapse or recurrence of, 379
 serious and community-based programs for, 400–403
 statistics, 1
 substance use disorders and, 184
 suicide and, 2
 mental status examination (MSE), 48–49, 60, 87, 117, 171, 273, 298, 417–418
 electronic medical record system (EMR) and, 43, 481
 electronic medical record system (EMR) checklist, 48
 laboratory evaluation and, 49
 mini, 284
 neurocognitive disorders and, 273
 psychotic symptoms and, 118
 substance intoxication and, 190
 mentalization-based treatment (MBT), 250, 254
 mesocortical pathway, 21
 mesolimbic system, 23
 methadone, 196, 204, 217, 229
 maintenance treatment facilities usage in, 217
 opioid use disorders and, 208, 371–372
 opioid use disorders treatment, 211–212
 pharmacogenomics and, 221
 methamphetamine, 181, 184
 Miller, William, 403
 mind-body therapies, 407–408
 biological mechanisms and, 409
 historical perspective, 408–409
 mindfulness-based cognitive therapy (MBCT), 409
 mindfulness-based eating awareness therapy (MB-EAT), 409
 mindfulness-based relapse prevention (MBRP), 409
 mindfulness-based stress reduction (MBSR), 408
 Minnesota Multiphasic Personality Inventory (MMPI), 463
 minority stress theory, 458
 missing heritability, 15
 mixed mood episode, 75
 monoamine oxidase (MAO) inhibitors, 137, 256, 342, 376
 monoamine receptors
 blockade of, 19

506 Index

- monozygotic twins, 12, 19
 - and psychiatric disease, 13
- mood disorders, 27, 52, 64, 96, 104, 105, 117, 134, 136, 306, 318, 383, 415, *See also* depressive disorders, post-traumatic stress disorders (PTSD) and neuroimaging, 99
- DSM-5 Classification of, 70
- mood-stabilizing agents
 - adverse effects of, 368
- motivational enhancement therapies, 215–216
- motivational interviewing
 - approach, 194, 215, 216, 228, 403–407, 434
 - examples, 407
- naltrexone, 208–209, 221, 372
 - opioid use disorders treatment, 213
- narcissistic personality disorder (NPD), 253–254
 - treatment of, 253–254
- Narcotics Anonymous (NA), 216
 - meetings of, 230
- National Alliance on Mental Illness (NAMI), 403
- National Alzheimer's Plan (2011), 283
- National Center for Complementary and Alternative Medicine (NCCAM). *See* National Center for Complementary and Integrative Health (NCCIH)
- National Center for Complementary and Integrative Health (NCCIH),
- National Comorbidity Survey Replication (NCS-R), 129
- National Consensus Project Clinical Practice Guidelines for Quality Palliative Care, 440
- National Health Interview Survey, 407
- National Institute of Aging, 266
- National Institute of Mental Health (NIMH), 6, 10, 108, 157, 325
- National Institute on Drug Abuse, 227
- National LGBT Health Education Center, 463
- National Survey on Drug Use and Health (NSDUH), 184, 194, 477
- negative valence systems, 6
- negativism, 76
- neural circuits, 12, 28–30
 - identification of, 5
- neurobehavioral disorder, 186
- neurocognitive disorders
 - classification of, 263–264
 - criteria for, 264
 - due to Alzheimer's disease (AD), 268–269
 - due to other medical illnesses, 272
 - evaluation of, 273
 - HIV infection and, 271
 - Lewy bodies (NCDLB) and, 269–270
 - major, 268
 - major or mild, 265–266
 - medication/drug-induced, 272
 - mild, 266–267, 268
- neurodegenerative dementias, 270
- neurohormone systems, functioning of, 249
- neuroimaging, 5
- neurologic conditions
 - laboratory evaluation and, 97
- neurological disorders/illnesses (NCD), 82, 281–282, 486, 490
 - evaluation of patients with, 275
 - treatment of, 276
- neuromodulation approaches to mental health care, 7
- neuropharmacology, 221
- neurotherapeutics, 380
- neurotransmitters, 19–22
 - technologies for studying, 23–24
- nicotine dependence, 192, 371
- pharmacotherapy for, 213–214
- nicotine withdrawal, 180
- nicotinic acetylcholine receptors, 214
- nicotinic cholinergic signaling, 179
- nigrostriatal pathway, 21
- NIMH RDoC system, 7
- NMDA receptor antagonism, 182
- NMDA-mediated
 - glutamatergic excitatory neurotransmission, 179
- N-methyl-D-aspartate (NMDA) receptor antagonist, 375
- non-binary patients
 - psychological evaluation of, 464–465
- non-binary/gender-expansive identities, 452–453
- normative sadness, 86
- nosology, 10–12
- nucleosomes, 18
- nucleotides, 13
- obsessive-compulsive
 - personality disorder (OCPD), 150, 234, 254, 257–258
 - hoarding and, 147
 - treatment for, 257
- obsessive-compulsive and related disorders (OCRDs), 146, 151, 153
 - case examples, 159–161
 - clinical features, 149–151
 - criteria of, 146
 - diagnosis of, 151
 - epidemiology and impact, 148–149
 - etiological insights, 151
 - future directions, 156–158
 - sample interview questions, 158
 - semi-structured diagnostic interviews for, 153
- obsessive-compulsive disorders (OCD), 129, 146, 147
 - case example, 159
- Obsessive-Compulsive Inventory-Revised measure, 154

- treatment, 155–156
 olanzapine, 352
 one gene-one syndrome, 23
 opioid use disorders, 192
 buprenorphine as treatment for, 212
 detoxification from opioids, 207–208
 methadone as treatment of, 211–212
 naltrexone as treatment for, 213
 opioid withdrawal, 180, 192, 198, 207–208, 209, 212
 opioids, 180
 overdoses and, 180
 treatment of, 229–230
 opium poppy plant, 180
 optogenetics, 7
 Organization for Economic Cooperation and Development (OECD)
 universal health coverage, 473–474
 oxycodone, 204
 palliative care
 case examples, 444–445
 medicine, 440–443
 panic disorder, 131–132
 without agoraphobia, 142–143
 Panic Disorder Severity Scale (PDSS), 135
 paranoid personality disorder (PPD), 241–242
 prevalence of, 241
 treatment options and, 242
 paraphilic disorders, 462
 parasomnias, 334–335
 Parkinson's disease, 271
 paternal age, schizophrenia and, 110
 patient interview, 38, 427
 confidentiality and, 40
 developing interviewing skills, 43
 directioning, 42–43
 importance of safety and respect, 42
 importance of therapeutic alliance to, 39–40
 purpose of, 39–40
 setting boundaries, 38
 setting up (structure of), 42–43
 showing empathy and compassion, 40–41
 patients
 and capacity to make decisions, 66–68
 collateral history of, 423, 427
 diagnostic evaluation of, 421
 interviewing the, 427
 pedophilia, 395
 peer movement, 402
 peripartum onset, 94
 major depression and, 77
 persecutory delusions, 113
 persistent depressive disorder, 79–81
 personality disorders, 233–238, 424–426
 antisocial personality disorders (ASPD), 64, 246–247
 avoidant personality disorders (AVPD), 255–256
 borderline personality disorder (BPD), 76, 234, 247–251, 394, 396
 case examples, 259–260
 cluster B disorders, 245–246
 cluster C disorders, 254–255
 dependent personality disorders (DPD), 256–257
 dependent personality disorders (DPD) treatment, 255–256
 differential diagnosis and comorbidities, 236–238
 dysphoria in, 84
 future research and, 258
 histrionic personality disorder (HPD), 251
 histrionic personality disorder (HPD) treatment, 252–253
 narcissistic personality disorder (NPD), 253–254
 narcissistic personality disorder (NPD) treatment, 253–254
 obsessive-compulsive personality disorder (OCPD), 147, 150, 234, 257–258
 obsessive-compulsive personality disorder (OCPD) treatment, 257
 paranoid personality disorder (PPD), 241–242
 paranoid personality disorder (PPD) treatment, 242, 243
 pharmacologic treatments for, 238
 prevalence of, 234
 psychotherapy treatment for, 238
 sample interview questions and, 259
 schizoid personality disorder (SzPD), 242–243
 schizotypal, 102, 240
 schizotypal personality disorder (StPD), 244–245
 treatment of, 239–240
 personality type, hyperthymic personality, 96
 PET studies, 5
 pharmacodynamics, 15
 pharmacogenomics, 221
 genetic variation and, 15
 pharmacological treatments
 discovery of, 10
 personality disorders and, 235
 pharmacotherapy, 87, 277
 behavioral therapy use with, 219–220
 treatment for substance use disorders, 206
 phobia, specific, 132
 phobic neurosis, 129
 physical exam
 patient with MDD, 87
physioneurosis, 174
 pica, 294
 pleiotropy, phenomenon of, 4
 pluripotent stem cells (iPSCs), 12
 polygenic complex disorders, 4
 polygenic risk score (PRS), 17
 polysubstance use, 197
 population-based care
 and mental illness, 434
 population growth, US, 2

- positive valence systems, 6
 positron emission tomography (PET), 23
 post-traumatic stress disorder (PTSD), 129, 167, 168–169, 174, 175
 children and, 324
 course of, 169
 evaluation of patient with, 170–171
 prevention of, 171–172
 self-assessment questions and, 177–178
 treatment of, 172–174
 victims of domestic violence and, 57
 potentiation of glycine, 179
 potentiation of inhibitory GABA_A, 179
 pre-menstrual dysphoric disorder (PMDD), 81
 psychotic symptoms and, 82
 prescription amphetamines, 181
 prescription opioid, 192
 prescription stimulant, 184
 present illness
 history of, 45, 117, 298, 416, 417
 primary care
 and integration with
 behavioral health care, 3–4
 behavioral health integration and, 432–433
 primary care provider (PCP) and, 3
 Prion diseases, 271
 progressive cognitive deficits
 treatment of, 373–374
 Prolonged Exposure Therapy (PE), 172
 prophylactic treatment
 long-term, 367–368
 protein-coding sequence of
 DNA (exons), 14
 psychiatric assessment
 goals of a write-up, 43–44
 outline of, 44–50
 writing up the, 43–44
 psychiatric care
 inadequate access to, 477–478
 psychiatric conditions
 and stigma associated with, 7
 psychiatric consultation, 423, 436
 and diagnoses, 430–431
 approach to assessment, 422–423
 periodic follow-up, 428
 psychiatric disorders
 early onset of, 2
 genetics and, 4, 12–13
 heritability/heritability and, 4, 12–13
 prevalence of, 1–2
 prevalence of, in the United States, 140
 psychiatric diagnosis and
 suicide, 52
 psychotic symptoms and, 115
 recategorizing, 10
 spectrum disorders and, 5
 transdiagnostic approach and, 6
 understanding
 pathophysiology of, 9
 psychiatric emergencies
 self-assessment questions, 446–447
 psychiatric evaluation
 interview process, 416–417
 note of, 427
 psychiatric genetics, 4–5, 18–19
 and rare variants, 13–14
 research, 4
 Psychiatric Genomics Consortium, 16
 psychiatric illness
 past history of, 45–46
 pathophysiology of, 25
 present, 45
 psychiatric interview. *See*
 patient interview
 psychiatric symptoms and
 disorders
 scientific understanding of, 6
 psychiatrists, practicing
 decreasing numbers of, 2
 psychiatry
 clinical, 9
 consultation liaison, 422
 current and future directions
 of, 384–387
 emergency, 415–416
 emergency and focused
 medical assessment and, 419
 emergency safety risk
 assessment and, 418–419
 emergency valuation
 domains, 417
 emergency, patient history
 and physical examination, 419–420
 ethical issues and, 32–35
 gender identity and sexual
 orientation and, 456–458
 neuroscience and, 9
 psychiatric examination, 427
 psychiatric symptoms, 420, 421
 scientific basis of, 4–5
 psychoanalysis, 10, 391–392
 process, 392–393
 psychoeducation, 395
 psychoeducational and
 counseling therapies, 216
 psychoneuroendocrinology, 26
 psychoneuroimmunological
 mechanisms, 409
 psychopharmacologic
 treatments, 320
 psychosis
 acute, 121–122
 clinical examination and, 117–118
 initial medial work-up, 119
 laboratory investigation
 and, 118
 medical conditions
 associated with, 116
 post-psychotic phase of, 121–122
 psychotic symptoms and, 117
 psychosis diagnosis, 115–117
 psychosomatic medicine, 422
 psychostimulants, 376–377
 psychotherapy, 87
 and anxiety disorders, 138–139
 discussion about, 389–390
 evidence-based, 88
 treatment for personality
 disorders, 238

- psychotic disorders
 psychotic mood episodes, 95
 psychotic symptoms and, 52, 64, 75
 psychotic symptoms in adolescents, 30
 schizophrenia and, 153
 psychotic symptoms, in children, 324–326
 psychosis
 phase-specific treatment goals and challenges, 120
 psychiatric emergency treatment settings, 422

 rapid-acting antidepressants, 352–353
 reactive attachment disorder, 323
 rebound syndromes, 191
recombination, 16
 referring clinician, 428
 reinforcement, 187
 relapse prevention therapies, 206
 relaxation response (RR), 409
 religious delusions, 113
repetition compulsion, 174
 repetitive transcranial magnetic stimulation (rTMS), 157, 342, 380, 382
 efficacy of, 382–383
 safety and adverse effects of, 383
 representative assessment outline of, 44–50
 requesting physician speaking to, 423–427
 Research Domain Criteria (RDoC) project, 6, 18, 33
 framework, 10–12
 residential and inpatient treatment eating disorders and, 303–304
 restless legs syndrome (RLS), 333
 restraining orders, 60
 reuptake transporter, 22
 rumination disorder, 290, 294
 Rush, Benjamin, 9
 Rx for Survival, Global Health Champions, 1

 safety and respect, importance of, 42

 Saunders, Cecily, 440
 Saving Inventory-Revised measure, 155
 schema-focused therapy (SFT), 250
 schizoaffective disorder, 96, 104–105
 diagnostic criteria, 105
 schizoid personality disorder (SzPD), 242–243
 schizophrenia, 95, 102–103
 advanced paternal age and, 110
 burden of the illness, 108
 cannabis use and, 110
 classification of all spectrum disorders classification, 102
 clinical features and course of, 111–113
 cognitive impairment and, 272
 diagnosis of, 115–117
 diagnostic criteria, 103
 early brain development, 109–110
 electroconvulsive therapy (ECT) treatment for, 381
 etiological and pathophysiologic Insights, 123–125
 evaluation of, 117–120
 excess dopamine and, 19
 family history and, 109
 future directions, 125–126
 heritability/heritability and, 4
 life expectancy and, 402
 maintenance phase, 122–123
 neurocognitive testing, 119
 prevalence of, 108
 prodromal phase of, 121
 psychotic disorders and, 153
 psychotic symptoms and, 95, 111, 113
 risk factors for, 109–110
 self-assessment questions, 126–127
 sex ratio, 110
 skill deficit remediation and, 394
 socioeconomic status and, 110
 suicide risks and, 109
 symptoms of, 113–115
 treatment options and, 120
 schizophreniform disorder, 106
 schizotypal personality disorder, 102, 240, 244–245
 Schneider, Kurt, 113
 school-based prevention programs, 228
 Schou, Mogens, 364
 SCOFF, 299
 Screen, Assess and Refer (SAR) patients, 56
 screening and assessment screening questions for domestic violence and, 58–59
 screening questions, 49, 199, 299
 anxiety disorders and, 140
 substance use abuse and adolescents, 201
 violence risks and, 65
 screening tools for adolescents at risk of substance use disorders, 227
Screening, Brief Intervention, and Referral to Treatment (SBIRT), 406
 seasonal pattern, 82, 94
 depression and, 77
 secondary mood disorder, 95
 secretion of antidiuretic hormone (SIADH), 365
 sedative-hypnotics, 183
 detoxification from substance use, 206–207
 selective mutism, 322
 selective norepinephrine reuptake inhibitor (SNRIs), 377
 selective serotonin reuptake inhibitors (SSRIs), 19, 22, 136, 305, 344
 and treating depression in children, 319
 antidepressants, 173
 self-assessment questions clinical neurosciences, 36
 psychiatric emergencies and, 446–447
 schizophrenia, 126–127

- self-harm, 46, 57, 260
 - in depressed patients, 78
 - intentional, 51, 52
 - risk, 245
 - risk of, 97
 - safety evaluation, 418
- self-report instruments
 - OCRD assessment and, 154–155
- separation anxiety disorders and children, 322
- serious mental illness, community-based programs for, 400–403
- serotonin reuptake inhibitors (SRIs), 155
- serotonin system, 22
- serotonin-norepinephrine reuptake inhibitors (SNRIs), 19, 136, 173, 342, 344, 346
- sex assignment, 449
- sexual dysfunctions, 136, 361, 461–462
 - alcohol use and, 179
 - antidepressants and, 345, 348, 351
 - opioid use and, 180, 213
- sexual orientation, 448, 453–454
 - diversity of, 454
- shared psychotic disorder, 107
- shift work sleep disorder (SWSD), 338
- short-term antipsychotic treatment, 356–359
- shut-in personality, 240
- sickness behavior, 24
- SIGECAPS, 74
- siloed behavioral and physical health systems, 478–479
- single nucleotide polymorphisms (SNPs), 4, 15, 16, 123
- singleton siblings, 12
- skill deficit remediation, 394
- skin picking disorder (SPD), 146, 148, 155
 - case example, 160
 - Skin Picking Scale, 155
- sleep apnea. *See* sleep disorders
- sleep disorders, 329–338
 - central sleep apnea, 338, 339
 - delayed sleep phase disorder (DSPD), 337
 - excessive daytime sleepiness, 336
 - obstructive sleep apnea, 330
 - onset latency, 336
 - self-assessment questions, 340–341
 - sleep disturbances, 86
 - sleep-related breathing issues and, 338–339
- SMART Recovery, 204, 216
- smoking cessation, medication for, 181
- social and developmental history, patients', 48
- social anxiety disorder (SAD), 133
 - case examples, 143
 - children and, 323
- social phobia, 76, 133
- social processes, systems for, 6
- social rhythm therapy (IPSRT), 98
- SOCRATES (Stages of Change Readiness and Treatment Eagerness Scale), 205
- somatic delusions, 113, 296
- somatic symptom disorders, 436–438
- specific phobia, 132
 - and children, 322
- specified feeding or eating disorder (OSFED), 291
- sperm, 183, 456
 - copy number variations and, 110
- St. Christopher's Hospice, 440
- stepped care, 435–436
- steroids, anabolic-androgenic, 183
- Stevens, Nettie, 456
- Stevens-Johnson Syndrome, 365
- stimulants/stimulant use, 181–182, 193
- stimulus control techniques, 156, 331, 395, 397
- stress and trauma-related disorders, 166–168
- structural and functional MRI, 5
- Structured Clinical Interview for DSM Axis I Disorders (SCID), 134
- Substance Abuse and Mental Health Services Agency (SAMHSA), 199
- substance abuse disorders. *See* substance use disorders
- substance intoxication, 195
- substance use disorders, 2, 179, 352, 396
 - abstinence syndromes and, 190
 - abuse history of, 46–47
 - acute intoxication and, 190
 - acute opioid intoxication, 196
 - acute syndromes and, 195–197
 - agent, 187
 - alcohol use and, 191
 - assessment of substance use patterns and, 222
 - cannabis use and, 192
 - clinical evaluation and, 194
 - clinical features of, 189–190
 - cocaine and, 193
 - consequences of substance use and, 222
 - controllability, 222–223
 - core features of, 190
 - course of illness, 193–194
 - CRAFT screening of adolescents, 201–203
 - diagnosis and, 194
 - environmental factors and, 188–189
 - epidemiology of, 184–185
 - epigenetic factors and, 194
 - etiology of, 185
 - hallucinogens, 193
 - hereditary and, 185–187
 - history of, 222
 - host, 185–187
 - individual protective factors and, 194
 - individual risk factors and, 194
 - medical advice and, 204–205
 - office-based detection screening, 198–201
 - opioid use and, 192
 - other mental illnesses and, 184
 - patient readiness to change, 205–206
 - pharmacotherapy treatment options for, 206

- physical examination and biomarkers and, 191
 polysubstance use, 197
 prevention and early intervention in children, 227
 reinforcement and, 187
 safety issues and, 189
 schizotypal personality disorder and, 244
 screening of adolescents, 201
 screening of pregnant women, 201
 statistics for, 184–185
 stimulant use and, 193
 synthetic drug use and, 193
 tobacco use and, 191
 treatment options, 193, 206–207
 substance use screening process
 biomarkers and immunoassay, 203–204
 suicide/suicidality
 aborted/interrupted attempts, 51
 alcohol use disorders and, 184
 assessment of suicidality/suicidal thoughts, 50, 53–54, 55
 avoidant personality disorder (AVPD) and risk of, 255
 bipolar disorder and, 94
 historical risk factors for, 52
 interview elements, 55–56
 major depression and, 77–79
 mental illnesses and, 2
 mitigating factors for suicidality/suicidal thoughts, 54
 risk factors, 51–53
 schizophrenia and, 109
 suicidal thoughts, 53, 349
 suicidal thoughts and, 46, 87
 young adults and, 2
 supported employment, 402
 synaptic cleft, 19, 20, 21, 23, 376
 synaptic plasticity, 20
 synthetic cathinones, 181
 synthetic drug use, 193
 systemic illnesses, 95
 systems for social processes, 6
 Systems Training for Emotional Predictability and Problem Solving (STEPPS), 250
 tai chi, 408, 410
 task sharing, and mental health care, 489–491
 telehealth, 480
 telepsychiatry, 3
 therapeutic alliance and the patient interview process, 39–40
 Thorndike, Edward L., 456
 tic disorders, 152
 tobacco/tobacco use, 180–181, 191
 long-term effects of, 180
 short-term effects of, 180
 topiramate, 305, 306
 treatment for alcohol use disorders, 210
 transcendental meditation (TM), 408
 transcranial direct current stimulation (tDCS), 383
 transcranial magnetic stimulations (TMS), 156, 389
 transdiagnostic approach and psychiatric disorders, 6
 transference focused psychotherapy (TFP), 250, 254
 transgender, 451–452, 453, 458, 461, *See also* LGBTQ
 identity case conceptualization and recommendations for treatment, 468–469
 identity development and, 467–468
 in the DSM-III, 460
 psychiatric stigma for, 460
 psychological evaluation of, 464–465
 self-assessment questions, 471–472
 social needs of, 464
 transsexualism as a disorder, 460
 women, 454
 Transtheoretical Stages-of-Change Model, 205
 trauma, 166
 definition of reactions to, 166
 definition of traumatic events, 166
 epidemiology and impact of traumatic events, 167
 exposure to traumatic events, 166
 history of, 47
 stress-related disorders and, 166–168
 trauma and stressor-related disorders, children and, 323–326
 Trauma History Questionnaire, 171
 traumatic brain injury, 263, 270
 traumatic events and, 47
 traumatic events and hair pulling, 150
 traumatic neurosis, 174
 treatment
 Alzheimer's disease (AD), 283
 bipolar disorders, 97–98, 367
 borderline personality disorder (BPD), 249–251
 histrionic personality disorder (HPD), 252–253
 major or mild NCD and, 276
 narcissistic personality disorder (NPD), 253–254
 new treatments for dementia, 375
 obsessive-compulsive disorders, 155–156
 obsessive-compulsive personality disorder (OCPD), 257
 of mania in children, 320
 paranoid personality disorder (PPD), 243
 schizotypal personality disorder, 244–245
 treatment plan, patients', 50
 triage
 emergency psychiatry and, 415
 patients with psychiatric symptoms, 416
 trinucleotide repeats, 14

512 Index

twin studies/twins, 12–13, 19, 186 monozygotic and dizygotic, 12–13	universal health insurance coverage in the United States, 473 Unützer, Jürgen, 479 urine toxicology, 193, 196 cannabinoids users and, 192 cocaine use and, 196 drug abuse screening and, 421 opioid use and, 192 US Department of Health and Human Services, 478 US Food and Drug Administration (FDA), 342 vagus nerve stimulation (VNS), 383–384, 389 valproic acid, 98, 365 varenicline, 372–373 vascular neurocognitive disorders (VNCD), 269 Vietnam War, 188 violence clinical risk factors and, 63–64 mental illness patients and, 62–63 neurologic impairment and the risk for violence, 64 risk factors for, 63 sample questions, 65–66	treatments and interventions, 66 violence risk assessment, 64–65, 66 Wernicke, Karl, 9 withdrawal seizures, and alcohol, 179 withdrawal syndromes, 190, 206, 379–380, 417 stabilization of, 197–198 World Health Organization (WHO), 109, 184, 486 and the Mental Health Gap program, 490 World Professional Association for Transgender Health (WPATH), 464 Yale-Brown Obsessive-Compulsive Scale, 154 Yogi, Maharishi Mahesh, 409 young adults anorexia nervosa (AN) and, 303 delayed circadian phase and, 337 social anxiety disorder (SAD) and, 323 suicide and, 2, 136, 173, 349
--	--	--